XOMA

XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with various assets that provides right to future potential royalty and milestone payments. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.

EMERYVILLE, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA's Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share.

XOMA Royalty Declares Quarterly Preferred Stock Dividends

XOMA Royalty (XOMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes XOMA Royalty (XOMA) a New Buy Stock

XOMA Royalty (XOMA) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.60 per share a year ago.

XOMA Royalty (XOMA) Reports Q3 Loss, Tops Revenue Estimates

Zevra's MIPLYFFA™ (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty's portfolio

XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities

XOMA Royalty has acquired 50 percent of Twist's existing royalty and milestone economics for $15 million XOMA Royalty's portfolio now holds over 100 assets ranging from revenue-generating commercial therapeutics to pre-clinical programs EMERYVILLE, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) announced today it has entered into a $15 million royalty monetization arrangement with Twist Bioscience Corporation to acquire a 50 percent economic interest in all future milestones and royalties associated with the 60-plus partnered early-stage programs across 30 partners enabled by Twist Bioscience's Biopharma Solutions business unit.

XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience

Twist Bioscience Corp

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it has entered into a royalty purchase agreement with XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator. Under the terms of the agreement, XOMA Royalty will provide Twist Bioscience an upfront payment of $15 million in cash in exchange for the right t.

Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash

XOMA Royalty Corporation offers diversified revenue streams from milestone and royalty rights in various therapeutic areas, providing stable returns with lower clinical trial risks. The company's preferred shares, XOMAP and XOMAO, offer high, reliable dividends, making them attractive for income investors seeking biotech exposure. XOMA's robust financials, including substantial cash reserves and non-dilutive financing, ensure the sustainability of dividend payments for many years.

XOMA Royalty's Preferred Shares: High-Yield Dividends From Biotech Royalties

Harrow Health Inc

abrdn Life Sciences Investors 

There are sectors that experience demand irrespective of economic climate. I like cold hard cash placed in my account. We discuss big dividends from healthcare, yields +8.3%.

I Am Banking On The Silver Tsunami With Big Dividends

XOMA (XOMA, Financial), a company engaged in biotechnology royalties, saw its stock price plummet by 5.36%, with the latest price reported at $25.91. The trading volume reached 3,638 shares, representing a turnover rate of 0.03% and a price fluctuation amplitude of 3.79%.

XOMA Stock Dips Amidst Biotech Sector Decline

EMERYVILLE, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today Zevra Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for MIPLYFFA™ (arimoclomol). MIPLYFFA™ is approved for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients two years of age and older. It is the sixth commercial asset in XOMA Royalty's growing royalty and milestone portfolio.

Zevra's MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)

EMERYVILLE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following September 2024 investor conferences:

XOMA Royalty to Present at Upcoming Investor Conferences in September

XOMA Royalty (XOMA) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.59 per share a year ago.

XOMA Royalty (XOMA) Reports Q2 Loss, Tops Revenue Estimates

Cash receipts totaled $22.6 million in 2Q24, inclusive of royalty income and milestones from  Day One Pharmaceuticals and Rezolute

XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities

Kimbell Royalty Partners

Royalty interests present a lucrative opportunity for passive income from the popularity and demand for certain goods.

My 2 Top Royalty Income Picks, Yields Up To 9.5%

Xoma (XOMA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Xoma (XOMA) Surges 6.4%: Is This an Indication of Further Gains?

XOMA Corporation operates as a biotechnology royalty aggregator, acquiring economic rights to milestones and royalties from approved or clinical-stage drugs. XOMA's diverse IP portfolio spans various therapeutic areas, including oncology, immunology, rare diseases, and acute pain, mitigating investment risks. The recent acquisition of Kinnate Biopharma extends XOMA's portfolio into oncology despite Kinnate selling its crown jewel, exarafenib, before the acquisition.

XOMA Corporation: A Hold Rating With Steady Income From Preferred Shares

Xoma (XOMA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Xoma (XOMA) Soars 15.6%: Is Further Upside Left in the Stock?

EMERYVILLE, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA's Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share.

XOMA Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has received an $8.1 million milestone payment from Viracta Therapeutics, Inc., related to Day One Biopharmaceuticals' recent sale of its Priority Review Voucher (PRV) for $108 million to an undisclosed buyer.

XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals' Sale of its Priority Review Voucher

AdTheorent Holding Company Inc

Rigetti Computing

Although there was a time when the stock market was solely the playground of the wealthy, it no longer takes money to make money on Wall Street. The democratization of investing means even those with only a few dollars to spare can start building a retirement nest egg — and it won't even cost you anything to buy and sell shares.

3 Crazy Good Stocks to Buy With $500 Right Now

LOS ANGELES--(BUSINESS WIRE)--LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to announce that the Company and NantCell, Inc. (“NantCell”), together with NantCell's parent company ImmunityBio, Inc. (“ImmunityBio”), have agreed to a mutual termination of the license of aldoxorubicin entered into in 2017. With the termination of the license agreement between LadRx and NantC.

LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License

EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that members of its Executive Team will participate in the H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ being held on May 20, 2024, in New York, NY.

XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ

Earned $9 million milestone upon U.S. Food and Drug Administration's approval of  Day One's OJEMDA™ (tovorafenib);  XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales

XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

XOMA is entitled to a mid-single digit royalty on global OJEMDA™ sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation EMERYVILLE, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has earned a $9 million milestone related to the U.S. Food and Drug Administration's (FDA) approval of Day One Biopharmaceuticals' New Drug Application (NDA) for OJEMDA™ (tovorafenib) for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

News for XOMA Stock (XOMA)